Verastem (VSTM) Stock Price

Verastem Price

NASDAQ·CLOSED
8.27
​
Market closed

Over the last 7 years Verastem grew revenue by 2.1% annually, reaching 30.91 M USD. For Verastem, the net margin of -677.6% is down versus -76.5% a few years ago. The consensus 12-month price target for Verastem is 13.50 USD, about 63.3% above where the stock trades today. Of 15 analysts, 14 rate the stock a buy — an overall Buy consensus.

Verastem stock price

Access this data via the Eulerpool API

Verastem business model & stock analysis

Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. The company is headquartered in Needham, Massachusetts and currently employs 135 full-time employees. The company went IPO on 2011-11-08. The firm is focused on developing and commercializing medicines to improve outcomes for patients with cancer. The firm operates in the segment of developing drugs for the treatment of cancer. The Company’s marketed and developing products include defactinib and VS-6766. Defactinib is an oral small molecule inhibitor of FAK and PYK2 that is being evaluated as a potential combination therapy for various solid tumors. The company is engaged in running clinical trials in cancers where there are limited treatment options, including leukemia, lymphoma, lung cancer, mesothelioma, ovarian cancer, head and neck cancer, colorectal cancer and pancreatic cancer. VS-6766 is an inhibitor of the RAF/MEK signaling pathway. VS-6766 blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK.

Frequently asked questions about Verastem

Analysts currently set an average price target of 13.83 USD for the Verastem stock (median: 13.50 USD), implying +67.3 % versus the latest price. The consensus is based on 15 analyst ratings.

15 analysts currently rate the Verastem stock: 14 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Verastem to generate revenue of 117.93 M USD and earnings per share of -1.52 USD.

Converted at the current exchange rate, the Verastem share trades at 7.38 EUR (8.27 USD).

The Verastem share (VSTM) is listed on 5 stock exchanges, including: NASDAQ (VSTM), London (0LOV.L), Frankfurt (2VS.F), München (2VS.MU), Düsseldorf (2VS.DU).

The expected revenue of Verastem is 117.93 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Verastem is -127.14 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Verastem is currently -5.42. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Verastem stock.

The price-to-sales ratio (P/S) of Verastem is currently 5.85. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Verastem stock.

The Eulerpool Quality Score for Verastem is 4/10.

The ISIN of Verastem is US92337C2035. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Verastem is A1JTPU. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Verastem is VSTM. The ticker symbol is used to trade Verastem shares on the stock exchange.

Fair ValueTerminal
7.19 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
303,078.43 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website verastem.com
Currency
USD
Initial public offering
Nov 8, 2011
ISIN
US92337C2035
Cusip
92337C104
Sedol
B4Z1Y92
Market capitalization
637.64 M USDSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-5.42
P/Ee 2027
-6.29
P/Ee 2028
-6.92
P/Ee 2029
-12.10
P/Ee 2030
20.09
P/Se
5.85
EV/EBIT
—
P/B Ratio
11.15
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-150.63 %
Last updated Oct 8, 2026, 6:01 AM

Verastem Ticker

DÜSSELDORF · 2VS.DUFRANKFURT · 2VS.FLONDON · 0LOV.LMUNICH · 2VS.MUNASDAQ · VSTM

All fundamentals and in-depth analysis of Verastem

Our stock analysis for Verastem stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Verastem. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.